<SEC-DOCUMENT>0001213900-25-086488.txt : 20250910
<SEC-HEADER>0001213900-25-086488.hdr.sgml : 20250910
<ACCEPTANCE-DATETIME>20250910143513
ACCESSION NUMBER:		0001213900-25-086488
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250910
FILED AS OF DATE:		20250910
DATE AS OF CHANGE:		20250910

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NeuroSense Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001875091
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41084
		FILM NUMBER:		251305525

	BUSINESS ADDRESS:	
		STREET 1:		11 HAMENOFIM ST.
		STREET 2:		BUILDING B
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			4672562
		BUSINESS PHONE:		972-9-9531142

	MAIL ADDRESS:	
		STREET 1:		11 HAMENOFIM ST.
		STREET 2:		BUILDING B
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			4672562
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0256864-6k_neurosense.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Report of Foreign Private Issuer Pursuant to Rule&nbsp;13a-16
or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the Month of September 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission File Number: 001-41084</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NeuroSense Therapeutics Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>11 HaMenofim Street, Building B<BR>
Herzliya 4672562 Israel<BR>
+972-9-7996183<BR>
</B>(Address of principal executive office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Indicate by check mark whether the registrant files
or will file annual reports under cover Form&nbsp;20-F or Form&nbsp;40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form&nbsp;20-F&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form&nbsp;40-F&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 10, 2025, NeuroSense Therapeutics Ltd. issued a press
release reporting that it&rsquo;s drug candidate shows early signals of benefit in Alzheimer's patient-derived neurons.&nbsp;A copy of
the press release is furnished herewith as&nbsp;<A HREF="ea025686401ex99-1_neurosense.htm">Exhibit&nbsp;99.1</A>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Report on Form 6-K (including in Exhibit 99.1 only the language
prior to the reference to Mr. Alon-Ben Noon) is hereby incorporated by reference into the registrant&rsquo;s Registration Statements on&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390022005072/ea154846-s8_neurosense.htm">Form
S-8</A>&nbsp;(File No. 333-262480) and Form F-3 (File No.&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390023003838/ea171892-f3_neurosense.htm">333-269306</A>,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024030451/ea0203321-posam_neurosense.htm">333-260338</A>,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024106506/ea0223814-f3_neuro.htm">333-283656</A>&nbsp;and&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024112695/ea0226024-f3_neurosense.htm">333-284051</A>),
to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently
filed or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NeuroSense Therapeutics Ltd.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: September 10, 2025</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Alon Ben-Noon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alon Ben-Noon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea025686401ex99-1_neurosense.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; text-indent: 0pt; margin: 0pt"><B>Exhibit 99.1</B></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B><A NAME="ex99-1"></A>NeuroSense&rsquo;s Drug Candidate Shows Early
Signals of Benefit in Alzheimer&rsquo;s Patient-Derived Neurons</B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><I>Initial Phase 2 RoAD trial results demonstrate improvements
in brain-cell connectivity and health, with a favorable safety profile</I></P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">CAMBRIDGE, Mass., Sept. 10, 2025 /PRNewswire/ -- NeuroSense Therapeutics
Ltd.&nbsp;(Nasdaq: NRSN) (&ldquo;NeuroSense&rdquo;), a late-clinical stage biotechnology company developing novel treatments for&nbsp;severe
neurodegenerative diseases, today announced positive initial results from its collaboration with NeuroKaire in the ongoing RoAD Phase
2 clinical trial evaluating PrimeC for Alzheimer&rsquo;s disease (AD).</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Using NeuroKaire&rsquo;s proprietary technology to generate brain
cells from each patient&rsquo;s blood, analysis of samples from clinically characterized AD patients demonstrated that:&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">PrimeC
treatment enhanced neuroplasticity, a key feature in supporting brain health&nbsp;and&nbsp;function and underlying memory formation and
retention.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">No
treatment-related toxicity was observed, demonstrating the safety of PrimeC combination.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">NeuroSense&rsquo;s RoAD study is a randomized, double-blind, placebo-controlled
Phase 2 trial enrolling mild-to-moderate AD patients, designed to evaluate safety, efficacy, and biological activity of PrimeC over 12
months.</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">These results provide an early, patient-specific view of how
PrimeC may affect disease-relevant human neurons, reinforcing the program&rsquo;s mechanistic rationale and guiding precision development in
AD.</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">NeuroKaire&rsquo;s proprietary technology reprograms blood sample
cells into induced pluripotent stem cells (iPSCs) and differentiates them into mature human cortical neurons. After validation, neurons
are exposed to PrimeC, and advanced high-content imaging using AI-driven analytics quantifies key features of neuronal structure. This
generates composite response profiles tied to neuroplasticity, connectivity, and cell health.</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Alon Ben-Noon, CEO of NeuroSense, stated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><I>&ldquo;This is exactly the kind of early, decision-enabling signal RoAD was designed to uncover. By integrating NeuroKaire&rsquo;s patient-derived
neuron platform with our clinical program, we observed measurable gains in brain-cell connectivity and a favorable safety profile. These
findings strengthen PrimeC&rsquo;s mechanistic rationale in Alzheimer&rsquo;s and enable us to focus development with greater precision.&rdquo;</I></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt"><I></I></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><I>&nbsp;</I></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Dr. Daphna Laifenfeld, CSO of NeuroKaire, commented:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><I>&ldquo;Our platform is designed to detect subtle, disease-relevant changes in human neurons with the sensitivity modern drug development
requires. This collaboration demonstrates how a bench-to-clinic 360&deg; workflow can transform a simple blood draw into actionable, patient-specific
insights, accelerating innovation for people living with AD.&rdquo;</I></P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">These results will be presented at the CNS Summit 2025 in
Boston, November 2<SUP>nd</SUP> &ndash; 5<SUP>th</SUP> by David Pattison, VP Business Development at NeuroKaire.</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">NeuroSense and NeuroKaire will continue evaluating PrimeC&rsquo;s
cellular effects in parallel with clinical outcomes from the RoAD trial, with top-line data expected following study completion.</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>About Alzheimer&rsquo;s Disease</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><B></B>Alzheimer&rsquo;s disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide, affecting more than
30 million people globally. AD is characterized by memory loss, cognitive decline, and behavioral changes, and currently has no cure.
Existing therapies provide only limited symptomatic relief, leaving a significant unmet need for disease-modifying treatments that can
slow or halt progression. Given the complexity of AD, approaches that target multiple disease mechanisms simultaneously, such as PrimeC,
hold potential to deliver meaningful therapeutic advances for patients and their families.</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>About PrimeC</B></P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">PrimeC, NeuroSense&rsquo;s lead drug candidate, is a novel extended-release
oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed
to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation
and impaired ribonucleic acid (&ldquo;RNA&rdquo;) regulation to potentially inhibit the progression of ALS and AD.</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>About NeuroKaire</B></P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">NeuroKaire, founded in 2018 by Talia Cohen-Solal, Ph.D., and
Daphna Laifenfeld, Ph.D., is developing personalized medicine solutions to optimize treatment for psychiatric and neurological diseases.
The company&rsquo;s proprietary AI-powered platform, <I>Stemifai</I>, leverages stem cell differentiation and machine learning to inform and
advance CNS drug development processes. To learn more, follow us on&#8239;LinkedIn&#8239;or on Twitter&#8239;@Genetikaplus.</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>About NeuroSense</B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology
company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense
believes that these diseases, which include amyotrophic lateral sclerosis&nbsp;(ALS), Alzheimer&rsquo;s disease and Parkinson&rsquo;s disease, among
others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for
patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related
biomarkers, NeuroSense&rsquo;s strategy is to develop combined therapies targeting multiple pathways associated with these diseases.</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">For additional information, we invite you to visit our&nbsp;website&nbsp;and
follow us on&nbsp;LinkedIn, YouTube&nbsp;and&nbsp;X. Information that may be important to investors may be routinely posted on our website
and these social media channels.</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Forward-Looking Statements </B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">This press release contains &ldquo;forward-looking statements&rdquo;
that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words
such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;contemplate,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo;
&ldquo;intend,&rdquo; &ldquo;seek,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo;
&ldquo;project,&rdquo; &ldquo;target,&rdquo; &ldquo;aim,&rdquo; &ldquo;should,&rdquo; &ldquo;will&rdquo; &ldquo;would,&rdquo; or the negative of these
words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based
on NeuroSense Therapeutics&rsquo; current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to
predict and include statements regarding the results of the ongoing RoAD Phase 2 clinical trial evaluating PrimeC for Alzheimer&rsquo;s disease
(AD). Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The
future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the
forward looking statements. These risks include the risk that final results of the ongoing RoAD Phase 2 clinical trial evaluating PrimeC
for Alzheimer&rsquo;s disease (AD) will not be consistent with its positive initial results, the risk of a delay in submission by the Company
of its regulatory dossier,&nbsp;that regulatory approvals for PrimeC will be delayed or not obtained in Canada or elsewhere; unexpected
R&amp;D costs or operating expenses, insufficient capital to complete development of PrimeC, a delay in the reporting of additional results
from PARADIGM clinical trial, the timing of expected regulatory and business milestones, risks associated with meeting with the FDA and
Health Canada to determine the best path forward following the results from PARADIGM clinical trial, including a delay in any such meeting;
the potential for PrimeC to safely and effectively target ALS; preclinical and clinical data for PrimeC; the uncertainty regarding outcomes
and the timing of current and future clinical trials; timing for reporting data; the development and commercial potential of any product
candidates of Neurosense; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense&rsquo;s
filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future.
More information about the risks and uncertainties affecting NeuroSense is contained under the heading &ldquo;Risk Factors&rdquo; in the
Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 4, 2024 and NeuroSense&rsquo;s subsequent filings with
the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update
such information except as required under applicable law.</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">For further information: Email:&nbsp;info@neurosense-tx.com,
Tel: +972 (0)9 799 6183</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !5 4<# 2(  A$! Q$!_\0
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M;G>"R'*GB(X7Z_CISCAO;SBI*FZE*E72NFN632A._N3D?HU17Q]^R_\ MC^
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MNUZ\U/P=^RYI:>$=$B\Z";XG^*-+%WXGU(,[1--X4\-WP;3-%L;E5\^UU7Q
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M*?3[S5/NT\C[HXXY.!].W?U)/K7TE*K"K3C.FU)32:::ZJW3UU6Z>CLTF_\
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M;=H]+AU2]MH[B\\.:U96A%G;>([>QU>)X(+>RU#1;A+>VN+3\5]'^('[?/\
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MEA;//>W]U!9V5I%'Y\UWJ$[A+'3[2V"E[@S2/;RI;X;[3=NMDB&Z>)A_<S\
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M+V-W]LM;*YLY8H?/42W;VUI\$>'/^"(O[+>F^(+?5-:\5_%OQ3H]O+E- O\
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M:(NH_L1^R5^U=X'_ &MOA?)\1/!ND:_X6OM%\1:OX)\;^ _%=DMAXJ\$^,]
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MC'D>S:=];K2S5NNK*E6ITI0BFUSJ]X7E-I[*3ET3ZW;OT1^KZ@ X&  H" <
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3 HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
